US2017037006A1PendingUtilityA1
Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine
Est. expiryJun 16, 2026(expired)· nominal 20-yr term from priority
A61P 9/10A61P 3/04A61P 9/00A61P 7/12A61P 35/00A61P 25/22A61P 25/36A61P 25/14A61P 25/20A61P 25/32A61P 25/28A61P 25/34A61P 3/10A61P 25/06A61P 31/22A61P 25/24A61P 25/16A61P 25/02A61P 25/18A61P 25/04A61P 25/30A61P 25/00A61P 29/00A61P 19/02A61P 1/04A61P 19/10A61P 19/06A61P 1/18A61P 1/14A61P 1/08A61P 1/02A61P 11/00A61P 17/02A61P 19/08A61P 13/10A61P 21/00C07D 211/20C07C 229/24C07C 55/12C07C 55/08C07B 2200/13C07C 59/08
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.
Claims
exact text as granted — not AI-modified1 . Compound I, which is 4-[2-(4-methylphenylsulfanyl)phenyl]-piperidine
or a pharmaceutically acceptable salt thereof, in a crystalline form provided the compound is not 4-[2-(4-methylphenylsulfanyl)phenyl]-piperidine hydrochloride addition salt.
2 . The compound of claim 1 , wherein the compound is the HBr addition salt.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.